To understand the transcriptional impact of CDK9 inhibition beyond known targets such as MYC and MCL1, an unbiased transcriptomic analysis has identified DEGs that may be novel CDK9 gene targets in MYC+ DLBCL cell lines. The gene discussed is MCL1; the disease is diffuse large B-cell lymphoma.